Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute

被引:17
作者
Miyake, Makito [1 ]
Tanaka, Nobumichi [1 ]
Asakawa, Isao [2 ]
Hori, Shunta [1 ]
Morizawa, Yosuke [1 ]
Tatsumi, Yoshihiro [1 ]
Nakai, Yasushi [1 ]
Inoue, Takeshi [1 ]
Anai, Satoshi [1 ]
Torimoto, Kazumasa [1 ]
Aoki, Katsuya [1 ]
Hasegawa, Masatoshi [2 ]
Fujii, Tomomi [3 ]
Konishi, Noboru [3 ]
Fujimoto, Kiyohide [1 ]
机构
[1] Nara Med Univ, Dept Urol, 840 Shijo Cho, Nara 6348522, Japan
[2] Nara Med Univ, Dept Radiat Oncol, Nara, Japan
[3] Nara Med Univ, Dept Pathol, Nara, Japan
来源
BMC UROLOGY | 2017年 / 17卷
关键词
Prostate cancer; Brachytherapy; International Prostate Symptom Score; Overactive bladder symptom score; Biologically effective dose; PSA bounce; QUALITY-OF-LIFE; PERMANENT BRACHYTHERAPY; BIOCHEMICAL FAILURE; PSA BOUNCE; PREDICTIVE FACTORS; TRACT SYMPTOMS; CANCER; TOXICITY;
D O I
10.1186/s12894-017-0251-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The aim of this study was to evaluate the combined use of the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) as an assessment tool for urinary symptom flare after iodine-125 (I-125) implant brachytherapy. The association between urinary symptom flare and prostate-specific antigen (PSA) bounce was investigated. Methods: Changes in the IPSS and OABSS were prospectively recorded in 355 patients who underwent seed implantation. The percentage distribution of patients according to the difference between the flare peak and post-implant nadir was plotted to define significant increases in the scores. The clinicopathologic characteristics, treatment parameters, and post-implant dosimetric parameters were compared between the non-flare and flare groups. PSA bounce was defined as an elevation of >= 0.1 ng/mL or >= 0.4 ng/mL compared to the previous lowest value, followed by a decrease to a level at or below the pre-bounce value. Results: A clinically significant increase required an IPSS increase of at least 12 points and an OABSS increase of at least 6 points based on a time-course analysis of total scores and the QOL index. Assessment only by IPSS failed to detect 40 patients (11%) who had urinary symptom flare according to the OABSS. Univariate and multivariate analyses revealed that patients treated with higher biologically effective doses and those without diabetes mellitus had higher risks of urinary flare. There was no statistical correlation between the incidence and time of urinary symptom flare onset and that of a PSA bounce. Conclusions: To our knowledge, this is the first report to prove the clinical potential of the OABSS as an assessment tool for urinary symptom flare after seed implantation. Our findings showed that persistent lower urinary tract symptoms after seed implantation were attributed to storage rather than to voiding issues. We believe that assessment with the OABSS combined with the IPSS would aid in decision-making in terms of timing, selection of a treatment intervention, and assessment of the outcome.
引用
收藏
页数:11
相关论文
共 33 条
[1]   The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer [J].
Blaivas, Jerry G. ;
Weiss, Jeffrey P. ;
Jones, Mark .
BJU INTERNATIONAL, 2006, 98 (06) :1233-1237
[2]   Urinary symptom flare following I-125 prostate brachytherapy [J].
Cesaretti, JA ;
Stone, NN ;
Stock, RG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04) :1085-1092
[3]   Long-term urinary sequelae following 125iodine prostate brachytherapy [J].
Crook, Juanita ;
Fleshner, Neil ;
Roberts, Chris ;
Pond, Greg .
JOURNAL OF UROLOGY, 2008, 179 (01) :141-145
[4]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[5]  
Desai J, 1998, Radiat Oncol Investig, V6, P135
[6]   PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator [J].
Engeler, Daniel S. ;
Schwab, Christoph ;
Thoeni, Armin F. ;
Hochreiter, Werner ;
Prikler, Ladislav ;
Suter, Stefan ;
Stucki, Patrick ;
Schiefer, Johann ;
Plasswilm, Ludwig ;
Schmid, Hans-Peter ;
Putora, Paul Martin .
STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 (10) :787-791
[7]   Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy [J].
Eriguchi, Takahisa ;
Yorozu, Atsunori ;
Kuroiwa, Nobuko ;
Yagi, Yasuto ;
Nishiyama, Toru ;
Saito, Shiro ;
Toya, Kazuhito ;
Hanada, Takashi ;
Shiraishi, Yutaka ;
Ohashi, Toshio ;
Shigematsu, Naoyuki .
BRACHYTHERAPY, 2016, 15 (03) :288-295
[8]   Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence? [J].
Galego, Pedro ;
Silva, Fernando C. ;
Pinheiro, Luis Campos .
INTERNATIONAL BRAZ J UROL, 2015, 41 (02) :353-359
[9]   Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy [J].
Hackett, Cian ;
Ghosh, Sunita ;
Sloboda, Ron ;
Martell, Kevin ;
Lan, Lanna ;
Pervez, Nadeem ;
Pedersen, John ;
Yee, Don ;
Murtha, Albert ;
Amanie, John ;
Usmani, Nawaid .
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2014, 6 (03) :247-253
[10]   Symptom assessment tool for overactive bladder syndrome- Overactive bladder symptom score [J].
Homma, Yukio ;
Yoshida, Masaki ;
Seki, Narihito ;
Yokoyama, Osamu ;
Kakizaki, Hidehiro ;
Gotoh, Momokazu ;
Yamanishi, Tomonori ;
Yamaguchi, Osamu ;
Takeda, Masayuki ;
Nishizawa, Osamu .
UROLOGY, 2006, 68 (02) :318-323